Enveric Biosciences, Inc. - Common Stock (ENVB)
Competitors to Enveric Biosciences, Inc. - Common Stock (ENVB)
Baby D Pharmaceuticals, LLC
Though not publicly traded, Baby D Pharmaceuticals is focused on cannabinoid therapies and has gained traction in the therapeutic landscape. Their nimble approach and focus on personalized medicine could allow them to adapt and respond to market needs more swiftly than Enveric, which may give them an edge in a rapidly evolving space.
Compass Pathways plc CMPS -7.42%
Compass Pathways is at the forefront of the psychedelic medicine space, developing psilocybin therapies for treatment-resistant depression. Their substantial funding, robust clinical trial processes, and strong branding within the psychedelic sector position them as a formidable competitor against Enveric, which while operational in the same domain, lacks the same level of recognition and investment.
Ehave, Inc. EHVVF -23.33%
Ehave leverages technology to develop solutions for mental health, incorporating psychedelic therapy into their digital health platform. By combining technology with therapeutic modalities, Ehave differentiates itself somewhat from Enveric, which is more traditionally focused on clinical developments. However, Ehave's model may allow them to scale more efficiently, presenting a unique challenge.
Mind Medicine (MindMed) Inc. MNMD -5.22%
MindMed, similarly to Enveric Biosciences, develops psychedelic-inspired therapies, primarily targeting addiction and anxiety. MindMed's strong focus on clinical trials and innovative drug delivery systems provides them with a considerable competitive edge in advancing their products, while Enveric is still in earlier stages of development in some of its drug candidates.
Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals focuses on developing cannabinoid-based therapeutics for conditions like epilepsy and anxiety disorders, heavily competing with Enveric's focus on psychedelic therapeutics for mental health indications. Both companies are exploring the therapeutic potential of cannabis and psychedelics, but Zynerba has a more established pipeline and partnerships which could offer them an early market lead.